Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.

Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, Chauca-Diaz A, Johnson LK, Ng TL, Cambier JC, Clambey ET, Costello JC, Korman AJ, Theodorescu D.

Sci Adv. 2019 Feb 20;5(2):eaav2437. doi: 10.1126/sciadv.aav2437. eCollection 2019 Feb.

2.

SUMOylation Regulates Transcription by the Progesterone Receptor A Isoform in a Target Gene Selective Manner.

Abdel-Hafiz HA, Dudevoir ML, Perez D, Abdel-Hafiz M, Horwitz KB.

Diseases. 2018 Jan 2;6(1). pii: E5. doi: 10.3390/diseases6010005.

3.

Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.

Abdel-Hafiz HA.

Diseases. 2017 Jul 6;5(3). pii: E16. doi: 10.3390/diseases5030016. Review.

4.

Role of epigenetic modifications in luminal breast cancer.

Abdel-Hafiz HA, Horwitz KB.

Epigenomics. 2015 Aug;7(5):847-62. doi: 10.2217/epi.15.10. Epub 2015 Feb 17. Review.

5.

Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.

Knox AJ, Scaling AL, Pinto MP, Bliesner BS, Haughian JM, Abdel-Hafiz HA, Horwitz KB.

Breast Cancer Res. 2014 Aug 13;16(4):418. doi: 10.1186/s13058-014-0418-6.

6.

Post-translational modifications of the progesterone receptors.

Abdel-Hafiz HA, Horwitz KB.

J Steroid Biochem Mol Biol. 2014 Mar;140:80-9. doi: 10.1016/j.jsbmb.2013.12.008. Epub 2013 Dec 12. Review.

7.

Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation.

Abdel-Hafiz HA, Horwitz KB.

BMC Mol Biol. 2012 Mar 22;13:10. doi: 10.1186/1471-2199-13-10.

Supplemental Content

Loading ...
Support Center